Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript - PubMed (original) (raw)
Affiliations
- PMID: 8208549
Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript
A Moghul et al. Oncogene. 1994 Jul.
Abstract
The c-MET proto-oncogene product is a transmembrane tyrosine kinase receptor which was recently shown to transmit an array of important cellular responses induced by Hepatocyte Growth Factor (HGF). These biological effects include induction of mitogenesis, motogenesis, morphogenesis, metastogenesis and anti-tumor activity on a variety of epithelial cells. All of these processes are known to be associated with normal and abnormal tissue growth and development. The 190 kDa c-MET protein is encoded by a major transcript of 8 kilobases (kb), which is reported to be expressed predominantly in epithelial tissues. The expression pattern of c-MET mRNA and protein are drastically modified in many tumor tissues and cell lines. Currently, no information is available on the molecular mechanisms that regulate c-MET mRNA level. In the present communication, we report for the first time that the inflammatory cytokines such as IL-1 alpha, IL-6 and TNF-alpha, as well as TGF-beta 1, EGF, HGF and the steroidal hormones (estrogen, progesterone, tamoxifen and dexamethasone) markedly influence the steady-state levels of the 8 kb c-MET mRNA in human carcinoma cell lines derived from human tissues such as ovary, breast and endometrium. We demonstrate that c-MET receptor protein is present at high levels in primary tumors of human ovaries (clear cell carcinomas). We present evidence that the 8 kb c-MET mRNA undergoes rapid degradation with a half-life of less than 30 min and that this decay can be quickly inhibited by cycloheximide. Our results suggest that the expression of the c-met proto-oncogene resembles that of an immediate early response gene.
Similar articles
- Induction of met proto-oncogene (hepatocyte growth factor receptor) expression during human monocyte-macrophage differentiation.
Chen Q, DeFrances MC, Zarnegar R. Chen Q, et al. Cell Growth Differ. 1996 Jun;7(6):821-32. Cell Growth Differ. 1996. PMID: 8780895 - Modifications of the hepatocyte growth factor/c-met pathway by constitutive expression of transforming growth factor-alpha in rat liver epithelial cells.
Presnell SC, Stolz DB, Mars WM, Jo M, Michalopoulos GK, Strom SC. Presnell SC, et al. Mol Carcinog. 1997 Apr;18(4):244-55. Mol Carcinog. 1997. PMID: 9142219 - Expression of the Met/HGF receptor in normal and neoplastic human tissues.
Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM. Di Renzo MF, et al. Oncogene. 1991 Nov;6(11):1997-2003. Oncogene. 1991. PMID: 1719465 - Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene.
Vigna E, Naldini L, Tamagnone L, Longati P, Bardelli A, Maina F, Ponzetto C, Comoglio PM. Vigna E, et al. Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):597-604. Cell Mol Biol (Noisy-le-grand). 1994. PMID: 7981617 Review. - The hepatocyte growth factor and its receptor.
Galimi F, Brizzi MF, Comoglio PM. Galimi F, et al. Stem Cells. 1993 Jul;11 Suppl 2:22-30. doi: 10.1002/stem.5530110805. Stem Cells. 1993. PMID: 8401259 Review.
Cited by
- Impact of Neuron-Derived HGF on c-Met and KAI-1 in CNS Glial Cells: Implications for Multiple Sclerosis Pathology.
Takano T, Takano C, Funakoshi H, Bando Y. Takano T, et al. Int J Mol Sci. 2024 Oct 19;25(20):11261. doi: 10.3390/ijms252011261. Int J Mol Sci. 2024. PMID: 39457044 Free PMC article. - Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients.
Palle J, Hirsch L, Lapeyre-Prost A, Malka D, Bourhis M, Pernot S, Marcheteau E, Voron T, Castan F, Lacotte A, Benhamouda N, Tanchot C, François E, Ghiringhelli F, de la Fouchardière C, Zaanan A, Tartour E, Taieb J, Terme M. Palle J, et al. Cancers (Basel). 2021 Nov 5;13(21):5562. doi: 10.3390/cancers13215562. Cancers (Basel). 2021. PMID: 34771724 Free PMC article. - Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma.
Kordbacheh F, Farah CS. Kordbacheh F, et al. Cancers (Basel). 2021 Oct 30;13(21):5471. doi: 10.3390/cancers13215471. Cancers (Basel). 2021. PMID: 34771633 Free PMC article. Review. - SREBP Plays a Regulatory Role in LH/hCG Receptor mRNA Expression in Human Granulosa-Lutein Cells.
Li YX, Guo X, Gulappa T, Menon B, Menon KMJ. Li YX, et al. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4783-4792. doi: 10.1210/jc.2019-00913. J Clin Endocrinol Metab. 2019. PMID: 31150065 Free PMC article. - A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. Geller JI, et al. Pediatr Blood Cancer. 2017 Nov;64(11):10.1002/pbc.26565. doi: 10.1002/pbc.26565. Epub 2017 Apr 27. Pediatr Blood Cancer. 2017. PMID: 28449393 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous